why choose us

First received: October 13, 2023

Clinical Trial: AMPK-activation by Metformin in FSGS: AMP-FSGS

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Focal Segmental Glomerulosclerosis

Study Type: INTERVENTIONAL


Official Title: AMPK-activation by Metformin in FSGS: AMP-FSGS

Brief Summary: The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).

Read more